Early clinical data with an inhaled RNA interference candidate look promising, but there is still much to prove.
The second quarter promises big data reveals for Fibrogen, Travere, Argenx and Bavarian Nordic.
The next few months will see some important mid-stage Nash results, from Viking, 89Bio, Northsea and others.
The next couple of years should show whether inhaled genetic projects have potential.
Roche’s zinpentraxin alfa is out of the running, but Bristol, Blade, Pliant and others have contenders in the mid-stage idiopathic pulmonary fibrosis pipeline.
The Takeda-partnered project fazirsiran shows an impressive reduction in mutant protein, but questions about fibrosis remain.
Moderna, Biomarin and Daiichi Sankyo will begin 2023 with important data reveals.
With a mid-stage win in cholesterol lowering in the bag, attention turns to obesity.